Drug and medical device interactions

Stent thrombosis and personalizing clopidogrel therapy

Betti Giusti, Anna Maria Gori, Rossella Marcucci, Claudia Saracini, Anna Vestrini, Rosanna Abbate

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent implantation. However, major adverse cardiovascular events including the severe complication of stent thrombosis occur in patients taking dual antiplatelet therapy. Clopidogrel requires intestinal absorption and hepatic conversion to active metabolite by several cytochrome P450 isoenzymes, among which the CYP2C19 plays a pivotal role; then, the active metabolite inhibits ADP-stimulated platelet activation by irreversibly binding to the P2Y12 receptor. Several factors interacting with each other are involved in determining the variability of individual response to clopidogrel. Nongenetic factors include chronic persistent factors (e.g., age, diabetes) and acute phase transient factors (e.g., inflammation). Among the numerous genetic variants investigated, recently, the loss-of-function CYP2C19*2 polymorphism has been associated with a decreased metabolization of clopidogrel, poor antiaggregant effect, and increased cardiovascular events. In high risk vascular patients, who experience percutaneous coronary intervention with stent implantation, the CYP2C19*2 polymorphism is a strong predictor of the adverse cardiovascular events and particularly stent thrombosis. Ongoing and future prospective studies evaluating if an antiplatelet treatment tailored on individual characteristics of patients genetic variants, platelet phenotype, drug-drug interactions, as well as traditional and procedural risk factors are now urgently awaited in order to define the optimal therapeutic strategies and management providing the best benefit for a given individual patient.

Original languageEnglish
Pages (from-to)124-138
Number of pages15
JournalCurrent Pharmacogenomics and Personalized Medicine
Volume8
Issue number2
Publication statusPublished - 2010

Fingerprint

clopidogrel
Stents
Thrombosis
Equipment and Supplies
Pharmaceutical Preparations
Percutaneous Coronary Intervention
Blood Platelets
Therapeutics
Age Factors
Intestinal Absorption
Platelet Activation
Standard of Care
Acute Coronary Syndrome
Drug Interactions
Adenosine Diphosphate
Cytochrome P-450 Enzyme System
Isoenzymes
Aspirin
Blood Vessels
Prospective Studies

Keywords

  • Acute coronary syndromes
  • Antiplatelet therapy
  • Cytochrome P450 2C19
  • Loss-of-function polymorphism
  • Major adverse cardiovascular events
  • Stent

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Pharmacology
  • Molecular Biology
  • Genetics(clinical)

Cite this

Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Vestrini, A., & Abbate, R. (2010). Drug and medical device interactions: Stent thrombosis and personalizing clopidogrel therapy. Current Pharmacogenomics and Personalized Medicine, 8(2), 124-138.

Drug and medical device interactions : Stent thrombosis and personalizing clopidogrel therapy. / Giusti, Betti; Gori, Anna Maria; Marcucci, Rossella; Saracini, Claudia; Vestrini, Anna; Abbate, Rosanna.

In: Current Pharmacogenomics and Personalized Medicine, Vol. 8, No. 2, 2010, p. 124-138.

Research output: Contribution to journalArticle

Giusti, B, Gori, AM, Marcucci, R, Saracini, C, Vestrini, A & Abbate, R 2010, 'Drug and medical device interactions: Stent thrombosis and personalizing clopidogrel therapy', Current Pharmacogenomics and Personalized Medicine, vol. 8, no. 2, pp. 124-138.
Giusti, Betti ; Gori, Anna Maria ; Marcucci, Rossella ; Saracini, Claudia ; Vestrini, Anna ; Abbate, Rosanna. / Drug and medical device interactions : Stent thrombosis and personalizing clopidogrel therapy. In: Current Pharmacogenomics and Personalized Medicine. 2010 ; Vol. 8, No. 2. pp. 124-138.
@article{658007343ef6434690b7f480f7a53298,
title = "Drug and medical device interactions: Stent thrombosis and personalizing clopidogrel therapy",
abstract = "Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent implantation. However, major adverse cardiovascular events including the severe complication of stent thrombosis occur in patients taking dual antiplatelet therapy. Clopidogrel requires intestinal absorption and hepatic conversion to active metabolite by several cytochrome P450 isoenzymes, among which the CYP2C19 plays a pivotal role; then, the active metabolite inhibits ADP-stimulated platelet activation by irreversibly binding to the P2Y12 receptor. Several factors interacting with each other are involved in determining the variability of individual response to clopidogrel. Nongenetic factors include chronic persistent factors (e.g., age, diabetes) and acute phase transient factors (e.g., inflammation). Among the numerous genetic variants investigated, recently, the loss-of-function CYP2C19*2 polymorphism has been associated with a decreased metabolization of clopidogrel, poor antiaggregant effect, and increased cardiovascular events. In high risk vascular patients, who experience percutaneous coronary intervention with stent implantation, the CYP2C19*2 polymorphism is a strong predictor of the adverse cardiovascular events and particularly stent thrombosis. Ongoing and future prospective studies evaluating if an antiplatelet treatment tailored on individual characteristics of patients genetic variants, platelet phenotype, drug-drug interactions, as well as traditional and procedural risk factors are now urgently awaited in order to define the optimal therapeutic strategies and management providing the best benefit for a given individual patient.",
keywords = "Acute coronary syndromes, Antiplatelet therapy, Cytochrome P450 2C19, Loss-of-function polymorphism, Major adverse cardiovascular events, Stent",
author = "Betti Giusti and Gori, {Anna Maria} and Rossella Marcucci and Claudia Saracini and Anna Vestrini and Rosanna Abbate",
year = "2010",
language = "English",
volume = "8",
pages = "124--138",
journal = "Current Pharmacogenomics and Personalized Medicine",
issn = "1875-6921",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Drug and medical device interactions

T2 - Stent thrombosis and personalizing clopidogrel therapy

AU - Giusti, Betti

AU - Gori, Anna Maria

AU - Marcucci, Rossella

AU - Saracini, Claudia

AU - Vestrini, Anna

AU - Abbate, Rosanna

PY - 2010

Y1 - 2010

N2 - Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent implantation. However, major adverse cardiovascular events including the severe complication of stent thrombosis occur in patients taking dual antiplatelet therapy. Clopidogrel requires intestinal absorption and hepatic conversion to active metabolite by several cytochrome P450 isoenzymes, among which the CYP2C19 plays a pivotal role; then, the active metabolite inhibits ADP-stimulated platelet activation by irreversibly binding to the P2Y12 receptor. Several factors interacting with each other are involved in determining the variability of individual response to clopidogrel. Nongenetic factors include chronic persistent factors (e.g., age, diabetes) and acute phase transient factors (e.g., inflammation). Among the numerous genetic variants investigated, recently, the loss-of-function CYP2C19*2 polymorphism has been associated with a decreased metabolization of clopidogrel, poor antiaggregant effect, and increased cardiovascular events. In high risk vascular patients, who experience percutaneous coronary intervention with stent implantation, the CYP2C19*2 polymorphism is a strong predictor of the adverse cardiovascular events and particularly stent thrombosis. Ongoing and future prospective studies evaluating if an antiplatelet treatment tailored on individual characteristics of patients genetic variants, platelet phenotype, drug-drug interactions, as well as traditional and procedural risk factors are now urgently awaited in order to define the optimal therapeutic strategies and management providing the best benefit for a given individual patient.

AB - Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent implantation. However, major adverse cardiovascular events including the severe complication of stent thrombosis occur in patients taking dual antiplatelet therapy. Clopidogrel requires intestinal absorption and hepatic conversion to active metabolite by several cytochrome P450 isoenzymes, among which the CYP2C19 plays a pivotal role; then, the active metabolite inhibits ADP-stimulated platelet activation by irreversibly binding to the P2Y12 receptor. Several factors interacting with each other are involved in determining the variability of individual response to clopidogrel. Nongenetic factors include chronic persistent factors (e.g., age, diabetes) and acute phase transient factors (e.g., inflammation). Among the numerous genetic variants investigated, recently, the loss-of-function CYP2C19*2 polymorphism has been associated with a decreased metabolization of clopidogrel, poor antiaggregant effect, and increased cardiovascular events. In high risk vascular patients, who experience percutaneous coronary intervention with stent implantation, the CYP2C19*2 polymorphism is a strong predictor of the adverse cardiovascular events and particularly stent thrombosis. Ongoing and future prospective studies evaluating if an antiplatelet treatment tailored on individual characteristics of patients genetic variants, platelet phenotype, drug-drug interactions, as well as traditional and procedural risk factors are now urgently awaited in order to define the optimal therapeutic strategies and management providing the best benefit for a given individual patient.

KW - Acute coronary syndromes

KW - Antiplatelet therapy

KW - Cytochrome P450 2C19

KW - Loss-of-function polymorphism

KW - Major adverse cardiovascular events

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=77953763296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953763296&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 124

EP - 138

JO - Current Pharmacogenomics and Personalized Medicine

JF - Current Pharmacogenomics and Personalized Medicine

SN - 1875-6921

IS - 2

ER -